BrWsh Journ d Caner (1995) 71,[950][951][952][953][954][955][956] 9 © 1995 Stockton Press AJI nghts reserved 0007-0920/95 $12.00 Anti-tumour activity of photodynamic therapy in combination with mitomycin C in nude mice with human colon adenocarcinoma LW Ma, J Moan, HB Steen and V lani Department of BiophYsics, The Institute of Cancer Research, Montebello, 0310 Oslo 3, NorKay.
dynamic therapy (PDT) can be used for the treatment of many forms of cancer (Dougherty et al., 1990; Henderson, 1990) . In order to enhance the efficiency of this therapy, many expenmental approaches and clinical investigations have shown that combinations of PDT with other treatments, such as hyperthermia (Henderson et al., 1985) , ionising radiation (Kostron et al., 1986) , electric current (Ma et al., 1993a) , chemotherapeutic drugs (Cowled et al., 1987; Edell and Cortese, 1988; Jin et al., 1992) , immunological agents (Dima et al., 1990) or surgical operations (Vietri et al., 1991) , produce significant advantages and may become beneficial modalities in clinical treatment of cancer. It is known that PDT in combination with chemotherapy is a promising therapy. With combination treatment not only can the efficacy of cancer treatment be increased, but the dose of photosensitiser and chemotherapeutic drug can also be decreased, thus leading to a reduction in adverse sideeffects. Several studies have demonstrated that the effects of PDT can be potentiated by chemotherapeutic agents such as doxorubicin and methotrexate in vivo (Cowled et al., 1985a; Edell and Cortese, 1988) . PDT combined with anti-cancer drugs (bacillus Calmette-Guerin and misonidazole) enhances the anti-tumour activity of either therapy used alone (Gonzalez et al., 1986; Cho et al., 1992) . Glucocorticoids administered after PDT greatly potentiate the therapeutic effect, as shown by the reduced rate of recurrence of the tumours (Cowled et al., 1985b) . However, so far there are few reports exploring the mechanism of interaction between PDT and chemotherapeutic drugs. Some investigators have proposed that the enhanced effect of PDT combined with certain chemotherapeutic drugs may be associated with the sum of the damage induced by both modalities and with the cytotoxic effect of the drugs on capillaries, thereby inhibiting their recovery from damage caused by PDT (Cho et al., 1992) . For example, the potentiation of PDT with haematoporphyrin derivatives (HPD) by doxorubicin may be because (a) both doxorubicin and HPD accumulate in mitochondria (Berns et al., 1982) and both doxorubicin and PDT form toxic oxygen radicals (Handa and Sato, 1975; Moan et al., 1979) ; or (b) doxorubicin is known to affect the growth of various solid tumours and may cause sufficient injury to result in death of cells sublethally damaged by PDT (Beilnier and Lin, 1985) .
Recently, several reports have shown a synergism between PDT and bioreductive drugs (Henry and Isaacs, 1989; Bremner et al., 1992; Baas et al., 1994) . The rationale behind the combination of PDT and bioreductive drugs is to exploit the tumour hypoxia induced by PDT in order to activate the cytotoxic action of these drugs (Hirsch et al., 1987) . Mitomycin C (MMC) is a bioreductive drug and a well-known chemotherapeutic agent widely used for treatment of various types of cancer (Wakaki et al., 1958; Verweij and Pinedo, 1990) . A study by Baas et al. (1994) has revealed that combining PDT with MMC greatly improves the tumour response. Our previous work in vitro has shown that the intracellular uptake of Photofrin by WiDr cells (a human colon adenocarcinoma cell line) is increased by addition of MMC (Ma et al., 1992a) , and that the cytotoxicity of PDT is significantly enhanced by MMC (Ma et al., 1993b) . Moreover, it has been found that the sensitivity of cells to PDT can be increased by MMC by causing an increase in the fraction of cells in S-phase of the cell cycle before PDT (Ma et al., 1993b (see Results) , the mice were killed and the levels of Photofrin in tumours were measured. The method of determining the concentration of Photofrin in tissues has been described previously (Ma et al., 1992h) . Briefly, tissue was made into a sL ,pension by means of an Ystral mechanical homogeniser (J)ottingen, Germany). A solution of 1% sodium dodecyl sulphate (SDS) in I N perchloric acidmethanol (1:1, v/v) was chosen to bnrng the maximum amount of Photofrin into the supernatant (Gomer et al., 1985; Peng et al., 1987) .
After homogenisation, the samples were frozen, thawed, sonicated for 30 s, diluted 1:50 in the same solvent, sonicated once more, centrifuged at 1600 g for 10 min and, finally, the supernatants were collected. Approximately 75% of Photofrin from the tissue suspension can be extracted with this method (Peng et al., 1987) . Drug levels in the supernatants were quantitatively determined by recording fluorescence emission spectra of the samples using a Perkin-Elmer LS 50 B Luminescence spectrometer connected to a personal computer. The excitation wavelength was 404 nm, the slit width corresponded to a resolution of 5.0 nm and the emission wavelength was scanned from 550 to 700 nm. The background fluorescence from control samples was subtracted. Photofrin levels in the samples were determined by adding a known amount of the drug, similar to that already present in the extraction medium, and recording the emission spectra once more.
Measurement of cell cycle distribution After different treatments (PDT and/or MMC), the mice were killed and the tumours were excised and minced. Singlecell suspensions were prepared by a 1 h disaggreption using a modified enzyme cocktail containing 0.05% pronase and 0.2% collagenase (Brown et al., 1979) (Siemann et al., 1981) , while the peak with about 1.6-fold higher DNA content represents the GI phase of the aneuploid WiDr tumour cells with their S and G2/M phases at correspondingly higher fluorescence (Siemann and Keng, 1986) . Figure 1 shows a relative increase in the number of S-phase cells after addition of MMC (1 mg (without MMC). MMC alone: 1 mg kg-' or 5 mg kg-' MMC was injected i.p. into the mice for 12h or 24h followed 4h later by sample collection. PDT alone: the mice were given i.p. 20mg kg-' Photofrin for 24 h followed by irradiation. PDT combined with MMC: the mice were injected with I mgkg-' MMC 12h after administration of 20mg kg-' Photofrin, followed 12 h later by irradiation, while 5 mg kg-' MMC and 20mg kg-' Photofrin were given simultaneously for 24 h followed by irradiation. Fugue 2 DNA histograms of dead cells caused by single or combined treatment as described in Table II . The experimental conditions are described in Table II. and 2.0 times respectively compared with control samples (Table II) . The corresponding DNA histograms are shown in Figure 2 . For PDT treatment, the proportion of dead cells in the sample as measured by flow cytometry was approximately 13%. For PDT combined with MMC, the proportion of dead cells measured was about 20%.
In addition, when all of the tumour samples were collected 8 h after finishing the treatments as indicated in Table II , the results were similar to those shown in Table I , but with a smaller increase in the fraction of dead cells in S-phase and G2/M phase after the combined treatment (data not shown).
Effect of MMC on Photofrin uptake by the twnours
The effect of MMC on the uptake of Photofrin in the tumour tissues is shown in Figure 3 . This figure depicts the concentrations of Photofrin in tumours relative to that of a sample with Photofrin only at different times after the injection of 1 mg kg-' or 5 mg kg' MMC. For all samples, Photofrin concentrations in tumours were measured 24 h after injection of the drug. Figure 3 shows that when the mice were given either 1 mg kg-' or 5 mg kg-' MMC for 30 min followed by 24 h administration of Photofrin, there was a slight increase in Photofrin uptake by the tumours. Moreover, the uptake of Photofrin by the tumours was increased 1.5-fold over the control sample (Photofrin only), when 1 mg kg-' MMC was injected at 12 h after Photofrin administration for a further 12 h and 1.6-fold when 5 mg kg-' MMC plus Photofrin were given simultaneously for 24 h (Figure 3 ).
Effect of single or combined treatment on tumour growth Figure 4 shows the growth curves of the WiDr tumour after MMC and/or PDT. It can be seen that 1 mg kg-' MMC alone had no effect on the tumour growth, while 5 mg kg-' MMC alone had a slight retarding effect. Tumour growth in mice given light alone and MMC plus light did not differ significantly from the growth of control tumours (no sensitiser, no light) (data not shown). When the mice were injected i.p. with a non-toxic dose of MMC (1 mg kg-') 12 h after the injection of Photofrin (20mg kg-') and followed 12 h later by irradiation, a synergistic retarding effect of the two treatments on the growth of the tumour was observed, while concomitant administration of MMC (5 mg kg-') and Photofrin (20mg kg-') for 24 h followed by irradiation also resulted in a significantly increased anti-tumour effect of the two treatments (Figure 4 and Table III ). However, PDT (Table III) .
A slight increase in temperature (<40-C) in the tumours during light exposure was found, but it did not affect the growth rate of unsensitised tumours, i.e. light alone had no effect on the tumour growth as mentioned above.
Effect of PDT and PDT combined with MMC on normal tissue Figure 5 shows the response of normal skin on mouse foot to PDT or PDT combined with MMC. It seems that the skin response (oedema) induced by PDT combined with 5 mg kg-' MMC was slightly greater than that induced by PDT alone. The response of PDT combined with 1 mg kg-' MMC appeared to be insignificantly different from the response of PDT alone. Moreover, it was noted that for the combination of PDT and MMC the skin oedema peak value was delayed for several days as compared with that of PDT alone. How- potentiates PDT, while doxorubicin given after PDT is not as effective. In contrast, misonidazole (MISO) given immediately after PDT potentiates the effect of PDT significantly, while MISO administered before PDT slightly reduces the effect of PDT (Evensen and Moan, 1988) . On the other hand, MISO given 30 min before and after PDT treatment potentiates the tumour response (Gonzalez et al., 1986; Hirsch et al., 1987) . In a recent study, Baas et al. (1994) reported that MMC given 1S min before PDT enhances RlFI tumour response by a factor of 2, while MMC added immediately after illumination does not increase the effect of PDT. One possible explanation for this phenomenon is that drug access to tumours is limited by PDT-induced vascular occlusion when MMC is administered after illumination (Baas et al., 1994) . Also, in a murine bladder tumour model, an increased effect of PDT by MMC administered 48 h before PDT was observed by Cho et al. (1992) . In our experiment, MMC was given 12 h or 24 h before PDT because, under the present experimental conditions, enhanced Photofrin uptake by the tumours and an increased fraction of the tumour cells in S-phase of the cell cycle were observed 12 h and 24 h after addition of MMC. However, MMC is believed to have a half life of 8-48 min in plasma (Dorr, 1988 However, there are other data which also suggest that the effects of MMC on the cell cycle distribution may last for a long period. It is known that the primary mechanism of action of MMC is the formation of DNA cross-links, which presumably inhibit DNA synthesis and block progression through the cell cycle (Goldberg, 1%5). Our in vitro experiments have demonstrated that treatment with MMC can lead to an accumulation of WiDr cells in S and early G2 phase of the cell cycle (Ma et al., 1992c) . We have measured the duration of GI, S and GJ/M phases of the WiDr cell cycle in vitro to be 13h, 12h and lOh respectively (data not published). Most of the tumour cells (about 88%) were in GO/GI phase at the time when MMC was injected into the mice.
When MMC acts on cells in the C0/Gl phase, their progression in the cell cycle may be significantly retarded. Moreover, the cells are also blocked in S-phase. This may be so even if MMC has been completely eliminated from the tumour at this time point. This inference is in agreement with the results of the present work. As shown in Table I , an increased fraction of cells in S-phase was found 6-24 h after the addition of MMC.
It has been reported that doxorubicin and methotrexate increase uptake of HPD in Lewis lung tumours in vivo, while in vitro doxorubicin inhibits uptake of HPD in both Raji and Lewis lung carcinoma cells, and methotrexate has no effect on the uptake of HPD in either cell line (Cowled et al., 1987) . The reason for this discrepancy between the in vitro and in vivo results is not clear. In the present study, the finding that MMC enhanced WiDr tumour uptake of Photofrin is consistent with our in vitro work (Ma et al., 1992a) , in which we found a 1.3-to 2.7-fold increase in the cellular uptake of Photofrin in cultured WiDr cells after 2-8 h incubation with MMC.
It is difficult to formulate a satisfactory hypothesis to account for this enhancement in the tumour uptake of Photofrin by addition of MMC. MMC has been demonstrated to be capable of generating oxygen free radicals, which cause substantial damage to biological membranes (Trush et al., 1982) . Therefore, one may speculate that the permeability of the tumour cell membrane or the permeability of the wall of capillaries in the tumours may be increased by MMC. Thus, a passive entry of Photofrin into the tumour cells may be enhanced by the effects of MMC. We have found that light-induced damage to the membranes of NHIK 3025 cells leads to an increased uptake of sensitiser into the cells . In addition, it has been reported that the intracellular uptake of haematoporphyrin (HP) is related to the position of the cells in the cell cycle. The amount of cell-bound HP increases as the cells proceed through the cell cycle from GI to G2JM phase and is approximately doubled from GI to late G2 phase (Christensen and Moan, 1980 ). This finding is in agreement with one of our early studies (Ma et al., 1992a) , in which the cellular uptake of Photofrin in cultured WiDr cells was enhanced by MMC through partial retardation of the cells in the late part of interphase and in the M-phase of the cell cycle. In the present study, 12 h and 24 h after the administration of MMC to the mice, the number of tumour cells in S-phase was increased by a factor of 2.4-2.3 compared with controls (Table I ). This may be one of the reasons for the enhanced uptake of Photofrin by tumours exposed to MMC. However, although there was no significant increase in the fraction of S-phase cells after 30 mm administration of MMC (Table I) , increased uptake of Photofrin in the tumours was observed (Figure 3) . Certainly, the influence of MMC on the uptake of Photofrin by the tumours is not fully understood.
It is known that many therapies have a selective effect on cells in different phases of the cell cycle. For example, antimetabolism chemotherapeutic drugs have a specific killing effect on cells in S-phase. Cells in S-phase are more sensitive to treatment with hyperthermia or UV irradiation (Westra and Dewey, 1971; Han and Sinclair, 1969) . CeUls in mitosis and GI are particularly sensitive to X-rays (Dewey et al., 1970) , whereas cells near the middle and late part of interphase show the highest sensitivity to PDT (Christensen et al., 1981) . Our previous in vitro work showed a positive correlation between the ability of MMC to increase the fraction of WiDr cells in S-phase and its ability to potentiate PDT (Ma et al., 1993b) . This finding is consistent with the present results. As shown in Table II and Figure 2 , after PDT alone the tumour cells appeared to be more easily killed in S-phase than in other phases of the cell cycle. Furthermore, when the tumour cells were retarded in S-phase by MMC and then given PDT, the fraction of cells inactivated in S-phase was larger than that when the tumour cells were given PDT alone, in agreement with the fact that the antitumour effect of PDT is potentiated by MMC. These data indicate that MMC may be used clinically to retard tumour cells in a specific phase of the cell cycle where they are particularly sensitive to PDT and thus to optimise PDT efficiency.
Some investigations have shown that treatment with MMC or MISO plus light without photosensitiser produces increased delay of tumour growth compared with treatment with drug or light alone (Baas et al., 1994; Evensen and Moan, 1988) . In the present work, we did not observe an enhanced inhibition of the tumour growth by MMC plus light, most probably because in our experiments, 12 h and 24h after MMC administration, the drug was eliminated from the tumour before illumination. The slight hyperthermia caused by the light exposure had no cytotoxic effect.
Skin photosensitivity is a factor of significant concern in PDT. Although MMC did not reduce skin photosensitivity (Figure 5) , it was encouraging to find that no significant increase in PDT-induced skin oedema was observed when a low dose of MMC (1 mg kg-') was added, whereas PDT combined with the MMC of I mg kg-' resulted in a significantly increased inhibition of tumour growth as compared with PDT alone (Figure 4 ). This result indicates that MMC enhances PDT anti-tumour effect with some selectivity. Obviously, systematic studies of normal tissue damage induced by PDT and by PDT in combination with chemotherapeutic drugs are needed.
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